Lv3
400 积分 2025-11-10 加入
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
22小时前
待确认
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study
4天前
已完结
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
12天前
已完结
Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies
13天前
已完结
Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies
21天前
已完结
Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck
24天前
已完结
Efficacy and safety of systemic treatments for patients with recurrent/metastatic head and neck squamous cell carcinoma: A systematic review and network meta-analysis
1个月前
已完结
Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma ( ARIA )‐EAACI 2024–2025 Guidelines: From Evidence‐to‐Decision Frameworks to Digitalised Shared Decision‐Making Algorithms
3个月前
已完结
[Chinese expert consensus on the evaluation of allergen-specific immunotherapy outcomes（Wuhan, 2025）]
3个月前
已完结
CRB2 Activates an Epigenetic Axis to Promote Ferroptosis in Head and Neck Squamous Cell Carcinoma
3个月前
已关闭
皖公网安备34019202002308
